Retatrutide and Liver Fat: The MASLD Data That Changed the Conversation

Beyond Weight Loss

When retatrutide’s Phase 2 obesity data were first presented, the headline was the 24.2% mean weight loss, the largest ever recorded for a pharmaceutical agent. For researchers and clinicians focused on metabolic liver disease, though, another number mattered more: the approximately 82% relative reduction in liver fat seen at the highest dose.

That finding moved retatrutide out of the “promising obesity drug” category and into a different conversation. This one is about metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The liver fat data suggested that retatrutide might treat a disease that affects roughly a quarter of adults worldwide and for which effective drugs have been hard to find.

The Phase 2 Imaging Substudy

The Phase 2 obesity trial included an imaging substudy that measured liver fat using magnetic resonance imaging-proton density fat fraction (MRI-PDFF), the current gold standard for measuring liver fat without a biopsy. MRI-PDFF gives precise, repeatable measurements that can detect changes as small as 1-2 percentage points in absolute liver fat fraction.

The substudy enrolled 98 participants with MASLD and at least 10% liver fat. At 24 weeks, the primary endpoint, liver fat in the 12 mg group had fallen by 82.4% (relative), and 86% of participants had liver fat below 5%, the threshold that defines hepatic steatosis. At 48 weeks the reduction was 86.0%, and 93% of those scanned were below 5%.

To see how large this is, compare other drugs. GLP-1 receptor agonists such as semaglutide usually cut liver fat by 30-40% in relative terms. Tirzepatide has shown reductions of about 50-55% at its highest doses. The 82% reduction with retatrutide is well beyond any other incretin-based therapy so far, and it approaches the liver fat reductions seen after bariatric surgery.

Why Glucagon Is the Likely Driver

The most plausible explanation for retatrutide’s larger liver fat reduction is its glucagon receptor agonism. That is the component that sets it apart from all other approved or late-stage incretin therapies.

Glucagon has well-established direct effects on how the liver handles fat. In liver cells, glucagon receptor activation stimulates fatty acid oxidation, the process by which the cells break down stored triglycerides and burn the resulting fatty acids for energy. At the same time, glucagon signaling suppresses de novo lipogenesis, the pathway the liver uses to make new fat from carbohydrate.

More fat breakdown plus less fat production gives a strong net drop in liver fat. These are direct actions on liver cells, not just side effects of weight loss. Preclinical studies of glucagon receptor agonists have shown liver fat falling even without much change in body weight, which confirms that the mechanism works independently of a calorie deficit.

This explains the gap between retatrutide and other incretin therapies. Semaglutide and tirzepatide reduce liver fat mainly through weight loss and better insulin sensitivity, both of which reduce how much fat reaches and builds up in the liver. Retatrutide adds a third mechanism, direct clearance of liver fat through glucagon receptor agonism, on top of the weight loss and insulin sensitization it shares with those drugs. The result is an additive, possibly synergistic, effect on liver fat.

The Dedicated MASLD Analysis

The liver results come from a pre-specified substudy of the Phase 2 obesity trial in participants who had MASLD at baseline, published in Nature Medicine in 2024 (Sanyal et al.). It measured liver fat with MRI-PDFF. No liver biopsies were done, so the substudy could not show effects on liver inflammation, fibrosis stage or steatohepatitis activity; biopsies remain the definitive way to assess those. Those questions are left to Phase 3. SYNERGY-Outcomes, a trial separate from the TRIUMPH obesity program, is testing whether retatrutide prevents major adverse liver outcomes in adults with MASLD/MASH (see SYNERGY-Outcomes and MACELD explained).

Tissue evidence matters. MASLD runs on a spectrum: from simple steatosis (fat buildup without much inflammation), to MASH (fat buildup with inflammation and liver cell injury), to fibrosis and finally cirrhosis. Treatments that only reduce liver fat help, but they are incomplete. The main goal is to resolve the inflammation that drives the disease toward fibrosis and cirrhosis.

The Scale of the Unmet Need

MASLD affects an estimated 25% of adults worldwide, making it the most common chronic liver disease. Its rise closely tracks the obesity epidemic, since excess body fat is the main driver of fat buildup in the liver. Among people with MASLD, about 20-30% have MASH, and some of them will go on to significant fibrosis, cirrhosis or hepatocellular carcinoma.

Despite this huge burden, there have been very few drug options for MASLD and MASH. Resmetirom (a thyroid hormone receptor agonist) received FDA approval for MASH with moderate to advanced fibrosis in 2024, the first approved drug for this condition. Even so, treatment is still mostly lifestyle change (weight loss, diet and exercise), which works but is hard to keep up at the level needed to improve the liver meaningfully.

A drug that reliably cuts liver fat by 80% or more, brings liver fat back to normal in most treated patients and shows tissue-level improvement in MASH would be a major addition to the treatment options. The retatrutide data suggest it may be that drug.

Eli Lilly’s Hepatology Strategy

Lilly’s decision to run a dedicated Phase 3 liver program, SYNERGY-Outcomes, alongside the TRIUMPH obesity trials shows that it sees retatrutide’s value reaching well beyond obesity.

The dedicated MASLD pathway also sets retatrutide up for a possible hepatology indication: a separate regulatory approval for treating metabolic liver disease. If Phase 3 confirms the Phase 2 liver fat findings and the MASLD trial results, Lilly could seek approval for both obesity and liver disease. That would greatly widen the patient population and the clinical uses for the molecule.

A dual indication would also affect prescribing. A drug approved for both obesity and MASLD would be especially appealing for the large group of patients who have both, and they make up a big share of people seeking metabolic treatment.

Outstanding Questions

Several important questions remain for Phase 3 and post-marketing data. We do not know how long the liver fat reduction lasts after treatment stops. If fat builds back up in the liver after stopping retatrutide, long-term or indefinite treatment may be needed, mirroring the weight regain seen with every drug treatment for obesity.

Trials of typical length cannot establish the link between lower liver fat and hard clinical endpoints such as progression to cirrhosis, liver-related death or the need for a transplant. Longer-term observational data will be needed to show whether these large liver fat reductions lead to real reductions in liver disease progression.

In theory the liver fat effect comes mainly from glucagon, but the contribution of each receptor component (GLP-1, GIP, glucagon) has not been separated in clinical studies. Knowing how much each one contributes would help in designing next-generation drugs.

A Convergence of Indications

The liver fat data have changed how retatrutide is discussed. What began as an obesity program has grown into a possible dual-indication drug aimed at two of the world’s largest metabolic disease burdens. The glucagon receptor component was once seen mainly as a way to boost weight loss by raising energy expenditure. It now looks like the likely driver of a liver effect that may prove as important as the weight loss, or more so.

For the metabolic liver disease field, which has waited decades for effective drugs, the retatrutide data are a real turning point. The Phase 3 results will show whether that promise holds up at scale.